Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bolt Biotherapeutics, Inc. (BOLT : NSDQ)
 
 • Company Description   
Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

Number of Employees: 91

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.63 Daily Weekly Monthly
20 Day Moving Average: 332,974 shares
Shares Outstanding: 37.47 (millions)
Market Capitalization: $61.08 (millions)
Beta: 2.06
52 Week High: $19.79
52 Week Low: $1.39
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.89% -3.53%
12 Week -54.60% -48.97%
Year To Date -66.74% -59.36%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
900 CHESAPEAKE DRIVE
-
REDWOOD CITY,CA 94063
USA
ph: 650-665-9295
fax: -
sarah.mccabe@sternir.com http://www.boltbio.com
 
 • General Corporate Information   
Officers
Randall C. Schatzman - Chief Executive Officer and Director
William P. Quinn - Chief Financial Officer
Edgar G. Engleman - Director
James I. Healy - Director
Kathleen LaPorte - Director

Peer Information
Bolt Biotherapeutics, Inc. (CORR.)
Bolt Biotherapeutics, Inc. (RSPI)
Bolt Biotherapeutics, Inc. (CGXP)
Bolt Biotherapeutics, Inc. (BGEN)
Bolt Biotherapeutics, Inc. (GTBP)
Bolt Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 097702104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 37.47
Most Recent Split Date: (:1)
Beta: 2.06
Market Capitalization: $61.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.89 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.27
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 25.58%
vs. Previous Quarter: 12.33%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 60.04%
ROE
03/31/22 - -37.29
12/31/21 - -32.92
09/30/21 - -42.78
ROA
03/31/22 - -30.78
12/31/21 - -28.18
09/30/21 - -31.28
Current Ratio
03/31/22 - 10.16
12/31/21 - 8.87
09/30/21 - 9.39
Quick Ratio
03/31/22 - 10.16
12/31/21 - 8.87
09/30/21 - 9.39
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -4,718.52
12/31/21 - -7,824.68
09/30/21 - -13,626.20
Book Value
03/31/22 - 6.10
12/31/21 - 6.71
09/30/21 - 7.39
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.09
12/31/21 - 0.09
09/30/21 - 0.08
Debt-to-Capital
03/31/22 - 8.53
12/31/21 - 8.04
09/30/21 - 7.57
 

Powered by Zacks Investment Research ©